Mabel Álvarez
UDLA
77
Coauthors
7
Documentos
2
H-index Scopus
Volumen de publicaciones por año
Cargando gráfico
| Año de publicación | Num. Publicaciones |
|---|---|
| 2016 | 2 |
| 2017 | 1 |
| 2018 | 1 |
| 2020 | 3 |
Publicaciones por áreas de conocimiento
Cargando gráfico
| Área de conocimiento | Num. Publicaciones |
|---|---|
| Cáncer | 12 |
| Farmacología | 3 |
| Cuidado de la salud | 1 |
Publicaciones por áreas temáticas
Cargando gráfico
| Área temática | Num. Publicaciones |
|---|---|
| Enfermedades | 7 |
| Medicina y salud | 5 |
| Farmacología y terapéutica | 3 |
| Problemas sociales y servicios a grupos | 1 |
Principales fuentes de datos
| Origen | Num. Publicaciones |
|---|---|
| Scopus | 7 |
| Google Scholar | 1 |
| RRAAE | 0 |
Cargando gráfico
Coautores destacados por número de publicaciones
| Coautor | Num. Publicaciones |
|---|---|
| Carmen Elena Viada | 7 |
| Aliuska Frías | 6 |
| Ballesteros J. | 4 |
| Tania Crombet | 4 |
| Martha M. Fors-López | 4 |
| Santiesteban Y. | 4 |
| García L. | 4 |
| Robaina M. | 3 |
| Macías A.E. | 3 |
| Camilo Rodríguez | 2 |
Cargando gráfico
Top Keywords
Cargando gráfico
Publicaciones del autor
Nimotuzumab for the treatment of patients with malignant glioma. Comparison between pre-registration and post-approved studies
ArticleAbstract: Nimotuzumab is a monoclonal antibody targeted against the epidermal growth factor receptor approvedPalabras claves:And High-grade glioma, Controlled clinical studies, nimotuzumab, Postmarking studies, Target therapiesAutores:Aliuska Frías, Carmen Elena Viada, García L., Luaces P.L.o., Mabel Álvarez, Macías A.E., Santiesteban Y., Saurez G., Tania CrombetFuentes:scopusEvaluation of racotumomab for the treatment of lung cancer: Meta-analysis of controlled trials of the CIM
ArticleAbstract: Racotumomab is a therapeutic cancer vaccine entirely developed in Cuba and licensed in the country fPalabras claves:immunotherapy, Non-small cell lung cancer, Oncological vaccines, Racotumomab, Vaccinal treatmentAutores:Alfonso S., Aliuska Frías, Ballesteros J., Carmen Elena Viada, Hernández M., Mabel Álvarez, Macías A.E., Martha M. Fors-López, Quintero J., Robaina M.Fuentes:scopusQuality of life assessment as a pbkp_redictor of survival in cancer
ArticleAbstract: The quality of life and survival are variables to take into account in the clinical trial of oncologPalabras claves:clinical trials, Oncology, quality of life, SurvivalAutores:Aliuska Frías, Ballesteros J., Bouza-Herrera C.N., Carmen Elena Viada, García L., Mabel Álvarez, Martha M. Fors-López, Ramos M., Santiesteban Y.Fuentes:scopusEvaluation of CIMAvaxEGF for the treatment of lung cancer: Meta-analysis of controlled clinical trials
ArticleAbstract: CIMAvaxEGF is a therapeutic cancer vaccine developed in Cuba and fully licensed in the country for uPalabras claves:EGF receptor, Epidermal growth factor, immunotherapy, Of non-small cell lung cancer vaccine therapy, Oncology vaccinesAutores:Aliuska Frías, Ballesteros J., Bárbara Wilkinson, Camilo Rodríguez, Carmen Elena Viada, Mabel Álvarez, Martha M. Fors-López, Neninger Vinageras E., Quintero J., Robaina M., Tania CrombetFuentes:scopusUnderlying dimensions of the EORTC QLQ-C30 in a Cuban population of patients with advanced non-small cell lung cancer
ArticleAbstract: Background: Quality of Life Core Questionnaire of the European Organization for the Research and TrePalabras claves:Confirmatory factor analysis, EORTC QLQ-C30, Item response theory, quality of lifeAutores:Aliuska Frías, Ballesteros J., Bárbara Wilkinson, Bouza-Herrera C.N., Camilo Rodríguez, Carmen Elena Viada, García L., Mabel Álvarez, MARTHA FORS, Martha M. Fors-López, Tania CrombetFuentes:googlescopus